American Public Education
APEI
46.05
-0.17
-0.37%
American Public Education
US · APEI
#3377 by market cap
46.05
-0.17
-0.37%
Live - 5344 symbols - heartbeat 310s ago
· 2026-10-08 04:07
Pre-market
46.21
+0.34%
After-hours
46.05
0.00%
- Market cap
- 842.79M
- P/E (TTM)i
- 18.95
- P/Bi
- 2.68
- EPSi
- 1.36
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on APEI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.20, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.89% YoY
Margins
- Gross margin
- 54.22%
- Operating margin
- 8.30%
- Net margin
- 3.90%
Key ratios & quality
- Enterprise valuei
- 774.73M
- Altman Z-Scorei
- 4.20
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 297.69M | 286.27M | 321.79M | 418.80M | 606.33M | 600.55M | 624.56M | 648.86M |
| Gross profit | 182.41M | 174.35M | 199.62M | 246.18M | 317.86M | 307.68M | 328.86M | 351.84M |
| Selling & admin expenses | 131.50M | 138.11M | 161.03M | 196.70M | 275.00M | 261.19M | 270.77M | 281.83M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 33.41M | 20.65M | 25.61M | 31.65M | 10.73M | 18.67M | 38.78M | 53.86M |
| Pretax profit | 35.44M | 16.66M | 25.85M | 26.09M | -151.25M | -52.77M | 30.94M | 43.71M |
| Tax | 9.29M | 5.19M | 7.02M | 7.51M | -36.28M | -10.72M | 10.42M | 12.15M |
| Net profit | 25.64M | 10.01M | 18.82M | 17.75M | -114.99M | -47.29M | 16.11M | 31.56M |
| Basic EPS | 2 | 1 | 1 | 1 | -6 | -3 | 1 | 1 |
| Diluted EPS | 1.54 | 0.62 | 1.25 | 0.97 | -6.10 | -2.94 | 0.57 | 1.40 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 164.55M | 162.77M | 163.22M | 158.33M | 174.74M | 171.73M |
| Gross profit | 89.61M | 84.34M | 88.52M | 89.38M | 100.11M | 95.09M |
| Selling & admin expenses | 71.61M | 73.20M | 70.83M | 66.20M | 74.16M | 77.61M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 14.00M | 7.06M | 13.74M | 19.05M | 21.80M | 13.53M |
| Pretax profit | 11.36M | 5.92M | 8.63M | 17.80M | 19.25M | 14.16M |
| Tax | 2.47M | 1.42M | 3.07M | 5.19M | 1.52M | 4.39M |
| Net profit | 8.89M | 4.50M | 5.56M | 12.61M | 17.73M | 9.77M |
| Basic EPS | 0 | 0 | 0 | 1 | 1 | 1 |
| Diluted EPS | 0.41 | -0.02 | 0.30 | 0.67 | 0.94 | 0.52 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 232.57M | 222.91M | 251.81M | 202.64M | 186.09M | 217.38M | 260.57M | 259.82M |
| Cash & ST investments | 212.13M | 202.74M | 226.49M | 122.63M | 102.52M | 116.66M | 131.93M | 174.10M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 370.96M | 354.90M | 371.02M | 725.61M | 615.06M | 557.39M | 570.10M | 521.42M |
| Total current liabilities | 44.33M | 45.28M | 55.06M | 83.68M | 70.76M | 73.99M | 79.16M | 75.05M |
| Short-term debt | -- | 2.28M | 2.39M | 22.46M | 14.40M | 13.31M | 13.55M | 11.37M |
| Long-term debt | -- | -- | -- | 151.77M | 93.15M | 94.68M | 93.42M | 94.67M |
| Total liabilities | 49,692,000.00 | 58,164,000.00 | 64,093,000.00 | 309,996,000.00 | 265,329,000.00 | 265,410,000.00 | 266,224,000.00 | 226,636,000.00 |
| Total equity | 321.27M | 296.73M | 306.93M | 415.61M | 349.73M | 291.98M | 303.88M | 294.78M |
| Retained earnings | 133.93M | 105.96M | 111.18M | 128.93M | 13.89M | -49.10M | -41.81M | -16.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 272.51M | 234.96M | 259.11M | 259.82M | 282.13M | 282.52M |
| Cash & ST investments | 161.60M | 174.95M | 191.35M | 174.10M | 217.60M | 221.60M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 578.66M | 537.37M | 525.30M | 521.42M | 537.91M | 537.75M |
| Total current liabilities | 83.43M | 82.91M | 91.39M | 75.05M | 94.54M | 86.96M |
| Short-term debt | 13.49M | 13.45M | 11.67M | 11.37M | 16.25M | 16.73M |
| Long-term debt | 93.75M | 94.06M | 94.37M | 94.67M | 83.20M | 81.64M |
| Total liabilities | 268,649,000.00 | 265,129,000.00 | 245,960,000.00 | 226,636,000.00 | 231,749,000.00 | 223,689,000.00 |
| Total equity | 310.01M | 272.24M | 279.34M | 294.78M | 306.17M | 314.06M |
| Retained earnings | -34.34M | -34.67M | -29.11M | -16.50M | 231.00K | 6.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 44.18M | 38.37M | 44.81M | 16.27M | 29.22M | 45.51M | 48.87M | 61.97M |
| Depreciation & amortization | 17.50M | 15.60M | 12.98M | 17.83M | 32.13M | 27.82M | 19.30M | 16.15M |
| Free cash flow | 34.75M | 31.12M | 39.88M | 4.44M | 12.83M | 31.62M | 27.79M | 46.10M |
| Dividends paid | -- | -- | -- | 0 | 0 | -6.01M | -6.06M | -2.75M |
| Stock buybacks / issuance | -1.82M | -40.51M | -15.71M | 83.17M | -1.54M | -10.74M | -4.24M | -4.26M |
| Ending cash balance | 212.13M | 202.74M | 227.69M | 149.63M | 129.46M | 144.34M | 158.94M | 176.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 37.00M | 14.81M | 21.71M | -11.55M | 63.30M | 12.14M |
| Depreciation & amortization | 3.99M | 4.09M | 3.95M | 4.12M | 4.15M | 3.95M |
| Free cash flow | 33.10M | 11.11M | 17.51M | -15.62M | 60.78M | 7.40M |
| Dividends paid | -1.43M | -1.32M | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -3.69M | -30.00K | -206.00K | -333.00K | -8.71M | -4.14M |
| Ending cash balance | 187.50M | 176.58M | 193.14M | 176.50M | 221.00M | 146.55M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.40 | 3.24 | 6.24 | 4.91 | -31.71 | -18.96 | 3.89 | 9.05 |
| ROA %i | 7.22 | 2.76 | 5.19 | 3.24 | -17.16 | -9.09 | 1.78 | 4.64 |
| ROIC %i | 7.70 | 2.32 | 5.78 | 3.64 | -19.53 | -10.18 | 2.46 | 6.15 |
| 5-year avg ROE %i | 11.59 | 8.53 | 7.02 | 6.08 | -1.78 | -7.25 | -7.12 | -6.56 |
| EBIT margin %i | 11.22 | 7.21 | 7.96 | 7.56 | 1.77 | -8.04 | 5.29 | 7.39 |
| FCF / sales %i | 11.67 | 10.87 | 12.39 | 1.06 | 2.12 | 5.27 | 4.45 | 7.10 |
| Current ratioi | 5.25 | 4.92 | 4.57 | 2.42 | 2.63 | 2.94 | 3.29 | 3.46 |
| Quick ratioi | 5.12 | 4.77 | 4.43 | 1.96 | 2.09 | 2.27 | 2.47 | 3.24 |
| Debt / assetsi | 0.00 | 3.32 | 2.38 | 33.59 | 33.98 | 36.73 | 35.19 | 31.25 |
| LT debt / equityi | -- | 3.20 | 2.10 | 53.24 | 62.76 | 75.87 | 70.81 | 51.42 |
| Interest coveragei | -- | -- | -- | -- | -- | -10.83 | 15.55 | 11.33 |
| Revenue CAGR (3Y) %i | -3.17 | -2.95 | 2.45 | 12.05 | 28.42 | 23.12 | 14.25 | 2.29 |
| Net income CAGR (3Y) %i | -7.52 | -25.44 | -3.77 | -11.53 | -- | -- | -3.18 | -- |
| FCF CAGR (3Y) %i | 5.32 | -7.74 | 6.36 | -49.64 | -25.58 | -7.45 | 84.33 | 53.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 7.14 | 7.43 | 9.13 | 9.05 | 12.34 | 15.58 |
| ROA %i | 3.26 | 3.53 | 4.42 | 4.64 | 6.37 | 8.50 |
| ROIC %i | 4.45 | 4.20 | 5.93 | 6.15 | 8.35 | 9.76 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.32 | 6.64 | 7.71 | 7.39 | 8.45 | 9.31 |
| FCF / sales %i | 7.30 | 7.79 | 9.16 | 7.10 | 11.20 | 10.49 |
| Current ratioi | 3.27 | 2.83 | 2.84 | 3.46 | 2.98 | 3.25 |
| Quick ratioi | 2.44 | 2.59 | 2.66 | 3.24 | 2.75 | 3.00 |
| Debt / assetsi | 34.34 | 36.41 | 31.65 | 31.25 | 28.53 | 28.54 |
| LT debt / equityi | 68.52 | 66.93 | 55.34 | 51.42 | 44.82 | 43.54 |
| Interest coveragei | 13.90 | -- | 13.84 | 11.33 | 13.68 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Health is the largest reported line at 50.20% of revenue, across 3 reported segments.
- Military follows at 49.81%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Health50.20%
Military49.81%
Quote time 2026-10-08 04:07:18 · For reference only, not investment advice and not tailored to your situation.